Hav­ing shipped its first bench­top gene edit­ing de­vices, In­scrip­ta draws an­oth­er $150M from deep in­vestor well

In­scrip­ta is one big step clos­er to reach­ing its am­bi­tious vi­sion of vast­ly scal­ing and de­moc­ra­tiz­ing ac­cess to gene edit­ing. And in­vestors have thrown in …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER